Anti-diabetic effects including diabetic nephropathy of anti-osteoporotic trace minerals on diabetic mice

Nutrition

Volumn 27, Issue 4, 2011, Pages 488-495

  Maehira, Fusako ^a   Ishimine, Nau ^a   Miyagi, Ikuko ^a   Eguchi, Yukinori ^b   Shimada, Katsumasa ^a   Kawaguchi, Daisuke ^a   Oshiro, Yoshihide ^a  

^a UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Anti diabetes; Diabetic glomerulopathy; Pancreatic and renal gene expression; Soluble silicon; Stable strontium

Indexed keywords

ADIPONECTIN; CALCIUM CARBONATE; CORAL SAND; GLUCOSE; INSULIN; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SILICONE DERIVATIVE; SOLUBLE SILICON; STRONTIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; DRUG MECHANISM; ENERGY EXPENDITURE; GENE EXPRESSION; GENE LOCATION; GLOMERULOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; KIDNEY; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTOLERANCE; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; TISSUE DISTRIBUTION;

ADIPONECTIN; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE DENSITY CONSERVATION AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIETARY SUPPLEMENTS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; LEPTIN; MALE; MICE; MICE, INBRED STRAINS; OSTEOPOROSIS; PANCRELIPASE; PPAR GAMMA; SILICON; SILICON COMPOUNDS; SOIL; TRACE ELEMENTS;

ANTHOZOA; MUS;

EID: 79952445982     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.04.007     Document Type: Article

References (49)

1. O'Connell B.S. Select vitamins and minerals in the management of diabetes. Diabetes Spectrum 2001, 14:133-148.
2. Carlisle E.M. Silicon: an essential element for the chick. Science 1972, 178:619-621.
3. Carlisle E.M. Silicon. Biochemistry of the essential ultratrace elements 1984, 257-291. Plenum Press, New York. E. Frieden (Ed.).
4. Maehira F., Miyagi I., Eguchi Y. Effects of calcium sources and soluble silicate on bone metabolism and the related gene expression in mice. Nutrition 2009, 25:581-589.
5. Maehira F., Iinuma Y., Eguchi Y., Miyagi I., Teruya S. Effects of soluble silicon compound and deep-sea water on biochemical and mechanical properties of bone and the related gene expression in mice. J Bone Miner Metab 2008, 26:446-455.
6. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
7. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
8. Kahn S.E., Zinman B. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes. Diabetes Care 2007, 30:1672-1676.
9. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy-a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
10. Lazarenko O.P., Rzonca S.O., Hogue W.R., Swain F.L., Suva L.J., Lecka-Czernick B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669-2680.
11. Schwarz A.V., Sellmeyer D.E., Vittinghoff E., Palermo L., Lecka-Czernick B., Feingold K.R., et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endoclinol Metab 2006, 91:3349-3354.
12. Kahn S.E., Zinman B., Lachin J.M., Haffner S.M., Herman W.H., Holman R.R., et al. Rosiglitazone-associated fractures in type 2 diabetes. An analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 2008, 31:845-851.
13. Lecka-Czernick B., Gubrij I., Moerman E.J., Kajkenova O., Lipschitz D.A., Manolagas S.C., et al. Inhibition of OSF2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 1999, 74:357-371.
14. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U., Kubota N., et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
15. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., et al. The mechanism by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 2001, 276:41245-41254.
16. Scacchi R., Pinto A., Rickards O., Pacella A., De Stefano G.F., Cannella C., et al. An analysis of peroxisome proliferator-activated receptor gamma (PPAR-γ2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. Nutr Metab Cardiovasc Dis 2007, 17:632-641.
17. Lazarenko O.P., Rzonca S.O., Suva L.J., Lecka-Czernick B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006, 38:74-84.
18. Dahl S.G., Allain P., Marie P.J., Mauras Y., Boivin G., Ammann P., et al. Incorporation and distribution of strontium in bone. Bone 2001, 28:446-453.
19. Diani A.R., Sawada G.A., Zhang N.Y., Wyse B.M., Connell C.L., Vidmar T.J., et al. The KKAy mouse: a model for the rapid development of glomerular capillary basement membrane thickening. Blood Vessels 1987, 24:297-303.
20. Matthews D.R., Hosker J.P., Rundenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
21. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
22. Keiffer T.J., Habener J.F. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 2000, 278:E1-14.
23. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
24. Yoon M.J., Lee G.Y., Chung J.-J., Ahn Y.H., Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor-α. Diabetes 2006, 55:2562-2570.
25. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., Takekawa S., et al. Insulin/Fox 1 pathway regulates expression levels of adiponection receptors and adiponectin sensitivity. J Biol Chem 2003, 279:30817-30822.
26. Hollenberg A.N., Susulic V.S., Madura J.P., Zhang B., Moller D.E., Tontonoz P., et al. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J Biol Chem 1997, 272:5283-5290.
27. McGarry J.D., Dobbins R.L. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999, 42:128-138.
28. Schuit F.C., Huypens P., Heimberg H., Pipeleers D.G. Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 2001, 50:1-11.
29. Kim H.I., Ahn Y.H. Role of peroxisome proliferator-activated receptor-γ in the glucose-sensing apparatus of liver and β-cells. Diabetes 2004, 53:S60-S65.
30. Del Guerra S., Lupi R., Marselli L., Masini M., Bugliani M., Sbrana S., et al. Functional and molecular defects of pancreatic inslets in human type 2 diabetes. Diabetes 2005, 54:727-735.
31. Kawai T., Hirose H., Seto Y., Fujita H., Fujita H., Ukeda K., et al. Troglitazone ameliolates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res Clin Pract 2002, 56:83-92.
32. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARγ ligands increase expression and plasma concentrations of adiponection, and adipose-derived protein. Diabetes 2001, 50:2094-2099.
33. Kharroubi I., Rasschaert J., Eizirik D.L., Cnop M. Expression of adiponectin receptors in pancreatic β cells. Biochem Biophys Res Commun 2003, 312:1118-1122.
34. Sun X., Han R., Wang Z., Chen Y. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Diabetologia 2006, 49:1303-1310.
35. Huypens P., Moens K., Heimberg H., Ling Z., Pipeleers D., Van de Casteele M. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci 2005, 77:1273-1282.
36. Zhou Y.T., Shimabukuro M., Wang M.Y., Lee Y., Higa M., Milburn J.L., et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci USA 1998, 95:8898-8903.
37. Kendall D.M., Rubin C.J., Mohideen P., Ledeine J.-M., Belder R., Gross J., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with Muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy. A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006, 29:1016-1023.
38. Fernandes-Santos C., Carneiro R.E., Mendonca L.S., Aguila M.B., Mandarim-de-Lacerda C.A. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition 2009, 25:818-827.
39. Roduit R., Morin J., Masse F., Segall L., Roche E., Newgard C.B., et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-α gene in the pancreatic β-cell. J Biol Chem 2000, 275:35799-35806.
40. Jefferson J.A., Shankland S.J., Pichler R.H. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008, 74:22-36.
41. Kaene W.F. The role of lipids in renal disease: future challenges. Kidney Int 2000, 75:S27-S31.
42. Iwasaki T., Togashi Y., Terauchi Y. Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patients. Endocr J 2008, 55:311-316.
43. Leehey D.J., Kramer H.J., Daoud T.M., Chatha M.P., Isreb M.A. Progression of kidney disease in type 2 diabetes-beyond blood pressure control: an observational study. BMC Nephrol 2005, 6:8.
44. Buckingham R.E., Al-Barazanji K.A., Toseland C.D.N., Slaughter M., Connor S.C., West A., et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998, 47:1326-1334.
45. Park C.W., Zhang Y., Zhang X., Wu J., Chen L., Cha D.R., et al. PPAR-α agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006, 69:1511-1517.
46. Cha D.R., Zhang X., Zhang Y., Wu J., Su D., Han J.Y., et al. PPAR-α/γ agonist Tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007, 56:2036-2045.
47. Leeuwenkamp O.R., van der Vijgh W.J.F., Husken B.C.P., Lips P., Netelenbos J.C. Human pharmacokinetics of orally administered strontium. Calcif Tissue Int 1990, 47:136-141.
48. 32Si and accelerator mass spectorometry. J Inorg Biochem 1998, 69:177-180.
49. Reffitt D.M., Jugdaohsingh R., Thompson R.P.H., Powell J.J. Silicic acid: its gastrointestinal uptake and urinary excretion in man and effects on aluminium excretion. J Inorg Biochem 1999, 76:141-147.